Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Key PointsAlnylam's stock has plunged more than 40% this year, but the company's financials look great.
Key PointsAlnylam's stock has plunged more than 40% this year, but the company's financials look great.